View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSproutly Canada 過去の業績過去 基準チェック /06Sproutly Canadaの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 業界の成長23.06%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Nov 2021最近の業績更新Reported Earnings • Jan 30Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: CA$0.003 loss per share (up from CA$0.004 loss in 3Q 2021). Revenue: CA$94.6k (up 166% from 3Q 2021). Net loss: CA$1.13m (loss narrowed 6.4% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 31Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.007 loss in 2Q 2021)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2022 results: Revenue: CA$109.6k (down 44% from 2Q 2021). Net loss: CA$310.2k (loss narrowed 82% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.Reported Earnings • Jul 20Full year 2021 earnings released: CA$0.061 loss per share (vs CA$0.30 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: CA$316.4k (down 66% from FY 2020). Net loss: CA$16.4m (loss narrowed 73% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.Reported Earnings • Jan 31Third quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 3Q 2020)Third quarter 2021 results: Net loss: CA$1.21m (loss narrowed 16% from 3Q 2020).すべての更新を表示Recent updatesお知らせ • Sep 20Sproutly Canada Inc. (CNSX:SPR) executed a binding Letter of Intent to acquire Global assets of Apollon Formularies for CAD 7 million.Sproutly Canada Inc. (CNSX:SPR) executed a binding Letter of Intent to acquire Global assets of Apollon Formularies for CAD 7 million on September 12, 2023. After the successful completion of due diligence, Sproutly will acquire the assets of Apollon pursuant to an Asset Purchase Agreement. In exchange, Sproutly will issue to Apollon a sufficient number of Sproutly shares so that Apollon will own 49% of the enlarged shar capital of Sproutly, post-transaction. If the transaction takes place with the number of outstanding Sproutly shares as are currently in issue, and at an anticpated deemed price of CAD 0.02 (the price at which the trading of common shares of Sproutly was suspended), the effective valuation of the disposal of Apollon's assets will be CAD 7 million. The disposal of the assets will likely constitute a fundamental change to Apollon's business, and therefore an explanatory circular will be prepared and a general meeting called in due course, to obtain shareholder approval for the disposal.お知らせ • Sep 03Sproutly Canada Inc. announced that it has received CAD 0.1 million in fundingSproutly Canada Inc. announced a private placement of 6,666,666 units at a price of CAD 0.015 per unit for gross proceeds of CAD 100,000 on September 1, 2022. Each unit consisting of one common share and one non-transferable common share purchase warrant. Each warrant entitles the holder to acquire an additional common share at an exercise price of CAD 0.05 for a period of two years from the date of issue. All securities issued in connection with the private placement are subject to a four month and a day transfer restriction from the date of issuance. The private placement is subject to the approval of the Canadian Securities Exchange. The company paid finder's fees in the amount of CAD 8,000 through the issuance of 552,500 units on the same terms as described above.Reported Earnings • Jan 30Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: CA$0.003 loss per share (up from CA$0.004 loss in 3Q 2021). Revenue: CA$94.6k (up 166% from 3Q 2021). Net loss: CA$1.13m (loss narrowed 6.4% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 31Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.007 loss in 2Q 2021)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2022 results: Revenue: CA$109.6k (down 44% from 2Q 2021). Net loss: CA$310.2k (loss narrowed 82% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 17Sproutly Canada Inc. (CNSX:SPR) acquired Primary Assets of CannaHive Inc.Sproutly Canada Inc. (CNSX:SPR) acquired Primary Assets of CannaHive Inc. on August 16, 2021. Sproutly Canada Inc. (CNSX:SPR) completed the acquisition of Primary Assets of CannaHive Inc. on August 16, 2021.Reported Earnings • Jul 20Full year 2021 earnings released: CA$0.061 loss per share (vs CA$0.30 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: CA$316.4k (down 66% from FY 2020). Net loss: CA$16.4m (loss narrowed 73% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.お知らせ • May 08+ 1 more updateSproutly Canada, Inc. Completes the Formulation of Its Initial Beverage ProductsSproutly Canada Inc. announced it has completed the formulation of its initial beverage products and filed with Health Canada its NNCP notification related to cannabis-infused beverages utilizing cannabis extracts produced by the APP Technology. Sproutly's beverages deliver a predictable and rapid onset and offset of true to strain cannabis experiences that are not achieved by distillates and terpenes. The company's beverages are their second 2.0 product to be submitted, with the intended launch set for the third quarter of calendar 2021. The beverages are being launched under Sproutly's Caliber brand starting with the company's Lemon Z and Berry White strains to deliver a Sativa and an Indica experience, respectively. Each product will be available in both a single 2 ounce (60mL) bottle with whole plant extract that contains 5mg THC, and a single 8 ounce (237mL) bottle containing 10mg THC, the maximum allowed under Canada's Cannabis Act. The products will be sold under its Health Canada licensed subsidiary, Toronto Herbal Remedies Inc. ("THR") and leverage THR's current provincial supply agreements within Canada.お知らせ • Apr 16Sproutly Canada Inc. announced that it has received CAD 1.348302 million in fundingOn April 15, 2021, Sproutly Canada Inc. (CNSX:SPR) closed the transaction. The company issued 15,916,037 units for CAD 795,802 in its second and final tranche. The company issued a total of 26,966,037units for CAD 1,348,302 in the transaction. The transaction included participation from Arup Sen, Chief Executive Officer and director of the company through a company controlled by Sen participated for 3,000,000 units. The transaction is subject to the approval of Canadian Securities Exchange. The company will issuance of 450,000 units for CAD 22,500 to finders in the transaction.お知らせ • Mar 16Sproutly Canada Inc. announced a financing transactionSproutly Canada Inc. (CNSX:SPR) announced a private placement of units on March 15, 2021. Each unit consisting of one common share and one non-transferable common share purchase warrant. Each warrant entitles the holder to acquire an additional common share at an exercise price of CAD 0.07 for a period of two years from the date of issue. All securities issued in connection with the private placement are subject to a four month and a day transfer restriction from the date of issuance. The transaction is subject to the approval of the Canadian Securities Exchange. The company paid finder's fess of CAD 24,862.50 through issuance of 497,250 units. On the same date, the company issued 11,050,000 units at a price of CAD 0.05 for gross proceeds of CAD 552,500.Reported Earnings • Jan 31Third quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 3Q 2020)Third quarter 2021 results: Net loss: CA$1.21m (loss narrowed 16% from 3Q 2020).お知らせ • Jan 12Sproutly Enters into LOI with Cannahive IncSproutly Canada Inc. has executed a Letter of Intent to enter into a commercial relationship with CannaHive Inc. The agreement will allow Sproutly to further expand its Cannabis 2.0 product offerings produced by the Company’s wholly-owned subsidiary, Toronto Herbal Remedies Inc. Sproutly will leverage CannaHive’s proprietary manufacturing and packaging equipment and intellectual property to produce cannabis dissolvable powder at THR’s licensed facility. This agreement follows closely on the heels of the LOI with Cannabis Manufacturer’s Guild Ltd. These relationships will provide synergies for the branding, commercialization, and distribution of a portfolio of cannabis products through THR’s existing agreements with multiple provinces in Canada.お知らせ • Dec 18Sproutly Canada Inc. Enters Into LOI With Cannabis Manufacturer’s Guild LtdSproutly Canada Inc. has executed a Letter of Intent (the “LOI”) to enter into a commercial relationship with Cannabis Manufacturer’s Guild Ltd. (“CMG”). The agreement will allow Sproutly to expand and diversify its flower and Cannabis 2.0 product offerings utilizing brands developed by CMG and its affiliates (the “Acquired Products”), through the Company’s wholly-owned subsidiary, Toronto Herbal Remedies Inc. (“THR”). Sproutly will leverage CMG’s expertise in branding, commercialization, and distribution of cannabis products for underserved categories in the Canadian market. The agreement allows Sproutly to sell the Acquired Products and facilitate potential business-to-business sales of Sproutly’s proprietary whole plant extracts to CMG’s network of Guild members.分析記事 • Dec 02Would Sproutly Canada (CSE:SPR) Be Better Off With Less Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Nov 17Sproutly Canada, Inc. Announcea the Addition of A Supply Agreement with the Ontario Cannabis StoreSproutly Canada Inc. announced the addition of a supply agreement with the Ontario Cannabis Store ("OCS"), the Company's 6th provincial supply agreement to date. This announcement comes on the heels of the Company's October 15th announcement regarding receipt of the sales license from Health Canada for Cannabis 2.0 products directly to provinces. The Company's wholly-owned subsidiary, Toronto Herbal Remedies ("THR"), has entered into a cannabis supply agreement with the province of Ontario (the "Supply Agreement") through the OCS. Ontario will be the 6th province in Canada to carry the Company's CALIBER branded products ("CALIBER"), following Saskatchewan, Manitoba, and British Columbia earlier this year as well as Alberta & New Brunswick in 2019. With the receipt of the license amendment that now permits the Company to sell Cannabis 2.0 products, the Company is in a position to offer its full line of products to the OCS. This includes Caliber Flower, Caliber Reserve Flower and upcoming Cannabis 2.0 products that will use the Company's proprietary APP Technology to offer consumers products that aim to deliver unique experiences of different cannabis strains arising from advances in cannabis genetics.お知らせ • Nov 10Sproutly Canada Inc. Announces Its Sixth Provincial Supply AgreementSproutly Canada Inc. announced the addition of a supply agreement with the Ontario Cannabis Store, the Company’s 6th provincial supply agreement to date. This announcement comes on the heels of the Company’s October 15th announcement regarding receipt of the sales license from Health Canada for Cannabis 2.0 products directly to provinces. The Company’s wholly-owned subsidiary, Toronto Herbal Remedies (“THR”), has entered into a cannabis supply agreement with the province of Ontario (the “Supply Agreement”) through the OCS. Ontario will be the 6th province in Canada to carry the Company’s CALIBER branded products ("CALIBER"), following Saskatchewan, Manitoba, and British Columbia earlier this year as well as Alberta & New Brunswick in 2019. With the receipt of the license amendment that now permits the Company to sell Cannabis 2.0 products, the Company is in a position to offer its full line of products to the OCS. This includes Caliber Flower, Caliber Reserve Flower and upcoming Cannabis 2.0 products that will use the Company’s proprietary APP Technology to offer consumers products that aim to deliver unique experiences of different cannabis strains arising from advances in cannabis genetics.お知らせ • Sep 07Sproutly Canada Inc. Auditor Raises 'Going Concern' DoubtSproutly Canada Inc. filed its Annual on Aug 31, 2020 for the period ending Feb 29, 2020. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Aug 28Sproutly Canada Inc. announced that it has received CAD 0.96 million in funding from Infusion Biosciences Inc.Sproutly Canada Inc. (CNSX:SPR) announced a non-brokered private placement of 1,500,000 equity units at an issue price of 0.07 per equity unit for gross proceeds of CAD 105,000 and a secured convertible debenture for gross proceeds of CAD 855,000 and aggregate gross proceeds of CAD 960,000 on August 28, 2020. The debentures involved participation from returning investor Infusion Biosciences Inc. for CAD 855,000. The debentures carry an interest rate of 15% per annum and maturity date on or before October 24, 2020. The debenture will be convertible into debenture units a conversion price of CAD 0.07 per debt unit, subject to adjustment in accordance with the terms of the convertible debenture. Each debt unit will consist of one common share in the capital of the company and one common share purchase warrant, with each warrant entitling the investor to acquire one common share at an exercise price equal to CAD 0.08 for a period of two years from date of issuance. Each equity unit consists of one common share and one warrant, with each warrant entitling the holder to acquire one warrant share at an exercise price equal to CAD 0.08 for a period of two years from date of issuance. No finder's fees were paid in connection with the transaction. All securities issued in connection with the transaction will be subject to a four-month and one day hold period from their date of issue under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.収支内訳Sproutly Canada の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史CNSX:SPR 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費30 Nov 211-141031 Aug 210-131031 May 211-152028 Feb 210-162030 Nov 200-594031 Aug 201-595031 May 201-616029 Feb 201-628030 Nov 191-1210031 Aug 190-1210031 May 190-149028 Feb 190-138030 Nov 180-105031 Aug 180-93031 May 180-430質の高い収益: SPRが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: SPRの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: SPRの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: SPRの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: SPRの過去 1 年間の収益成長がPharmaceuticals業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: SPRは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/07/06 16:52終値2024/04/08 00:00収益2021/11/30年間収益2021/02/28データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sproutly Canada Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Jan 30Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: CA$0.003 loss per share (up from CA$0.004 loss in 3Q 2021). Revenue: CA$94.6k (up 166% from 3Q 2021). Net loss: CA$1.13m (loss narrowed 6.4% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 31Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.007 loss in 2Q 2021)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2022 results: Revenue: CA$109.6k (down 44% from 2Q 2021). Net loss: CA$310.2k (loss narrowed 82% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Jul 20Full year 2021 earnings released: CA$0.061 loss per share (vs CA$0.30 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: CA$316.4k (down 66% from FY 2020). Net loss: CA$16.4m (loss narrowed 73% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Jan 31Third quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 3Q 2020)Third quarter 2021 results: Net loss: CA$1.21m (loss narrowed 16% from 3Q 2020).
お知らせ • Sep 20Sproutly Canada Inc. (CNSX:SPR) executed a binding Letter of Intent to acquire Global assets of Apollon Formularies for CAD 7 million.Sproutly Canada Inc. (CNSX:SPR) executed a binding Letter of Intent to acquire Global assets of Apollon Formularies for CAD 7 million on September 12, 2023. After the successful completion of due diligence, Sproutly will acquire the assets of Apollon pursuant to an Asset Purchase Agreement. In exchange, Sproutly will issue to Apollon a sufficient number of Sproutly shares so that Apollon will own 49% of the enlarged shar capital of Sproutly, post-transaction. If the transaction takes place with the number of outstanding Sproutly shares as are currently in issue, and at an anticpated deemed price of CAD 0.02 (the price at which the trading of common shares of Sproutly was suspended), the effective valuation of the disposal of Apollon's assets will be CAD 7 million. The disposal of the assets will likely constitute a fundamental change to Apollon's business, and therefore an explanatory circular will be prepared and a general meeting called in due course, to obtain shareholder approval for the disposal.
お知らせ • Sep 03Sproutly Canada Inc. announced that it has received CAD 0.1 million in fundingSproutly Canada Inc. announced a private placement of 6,666,666 units at a price of CAD 0.015 per unit for gross proceeds of CAD 100,000 on September 1, 2022. Each unit consisting of one common share and one non-transferable common share purchase warrant. Each warrant entitles the holder to acquire an additional common share at an exercise price of CAD 0.05 for a period of two years from the date of issue. All securities issued in connection with the private placement are subject to a four month and a day transfer restriction from the date of issuance. The private placement is subject to the approval of the Canadian Securities Exchange. The company paid finder's fees in the amount of CAD 8,000 through the issuance of 552,500 units on the same terms as described above.
Reported Earnings • Jan 30Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: CA$0.003 loss per share (up from CA$0.004 loss in 3Q 2021). Revenue: CA$94.6k (up 166% from 3Q 2021). Net loss: CA$1.13m (loss narrowed 6.4% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 31Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.007 loss in 2Q 2021)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2022 results: Revenue: CA$109.6k (down 44% from 2Q 2021). Net loss: CA$310.2k (loss narrowed 82% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 17Sproutly Canada Inc. (CNSX:SPR) acquired Primary Assets of CannaHive Inc.Sproutly Canada Inc. (CNSX:SPR) acquired Primary Assets of CannaHive Inc. on August 16, 2021. Sproutly Canada Inc. (CNSX:SPR) completed the acquisition of Primary Assets of CannaHive Inc. on August 16, 2021.
Reported Earnings • Jul 20Full year 2021 earnings released: CA$0.061 loss per share (vs CA$0.30 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: CA$316.4k (down 66% from FY 2020). Net loss: CA$16.4m (loss narrowed 73% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
お知らせ • May 08+ 1 more updateSproutly Canada, Inc. Completes the Formulation of Its Initial Beverage ProductsSproutly Canada Inc. announced it has completed the formulation of its initial beverage products and filed with Health Canada its NNCP notification related to cannabis-infused beverages utilizing cannabis extracts produced by the APP Technology. Sproutly's beverages deliver a predictable and rapid onset and offset of true to strain cannabis experiences that are not achieved by distillates and terpenes. The company's beverages are their second 2.0 product to be submitted, with the intended launch set for the third quarter of calendar 2021. The beverages are being launched under Sproutly's Caliber brand starting with the company's Lemon Z and Berry White strains to deliver a Sativa and an Indica experience, respectively. Each product will be available in both a single 2 ounce (60mL) bottle with whole plant extract that contains 5mg THC, and a single 8 ounce (237mL) bottle containing 10mg THC, the maximum allowed under Canada's Cannabis Act. The products will be sold under its Health Canada licensed subsidiary, Toronto Herbal Remedies Inc. ("THR") and leverage THR's current provincial supply agreements within Canada.
お知らせ • Apr 16Sproutly Canada Inc. announced that it has received CAD 1.348302 million in fundingOn April 15, 2021, Sproutly Canada Inc. (CNSX:SPR) closed the transaction. The company issued 15,916,037 units for CAD 795,802 in its second and final tranche. The company issued a total of 26,966,037units for CAD 1,348,302 in the transaction. The transaction included participation from Arup Sen, Chief Executive Officer and director of the company through a company controlled by Sen participated for 3,000,000 units. The transaction is subject to the approval of Canadian Securities Exchange. The company will issuance of 450,000 units for CAD 22,500 to finders in the transaction.
お知らせ • Mar 16Sproutly Canada Inc. announced a financing transactionSproutly Canada Inc. (CNSX:SPR) announced a private placement of units on March 15, 2021. Each unit consisting of one common share and one non-transferable common share purchase warrant. Each warrant entitles the holder to acquire an additional common share at an exercise price of CAD 0.07 for a period of two years from the date of issue. All securities issued in connection with the private placement are subject to a four month and a day transfer restriction from the date of issuance. The transaction is subject to the approval of the Canadian Securities Exchange. The company paid finder's fess of CAD 24,862.50 through issuance of 497,250 units. On the same date, the company issued 11,050,000 units at a price of CAD 0.05 for gross proceeds of CAD 552,500.
Reported Earnings • Jan 31Third quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 3Q 2020)Third quarter 2021 results: Net loss: CA$1.21m (loss narrowed 16% from 3Q 2020).
お知らせ • Jan 12Sproutly Enters into LOI with Cannahive IncSproutly Canada Inc. has executed a Letter of Intent to enter into a commercial relationship with CannaHive Inc. The agreement will allow Sproutly to further expand its Cannabis 2.0 product offerings produced by the Company’s wholly-owned subsidiary, Toronto Herbal Remedies Inc. Sproutly will leverage CannaHive’s proprietary manufacturing and packaging equipment and intellectual property to produce cannabis dissolvable powder at THR’s licensed facility. This agreement follows closely on the heels of the LOI with Cannabis Manufacturer’s Guild Ltd. These relationships will provide synergies for the branding, commercialization, and distribution of a portfolio of cannabis products through THR’s existing agreements with multiple provinces in Canada.
お知らせ • Dec 18Sproutly Canada Inc. Enters Into LOI With Cannabis Manufacturer’s Guild LtdSproutly Canada Inc. has executed a Letter of Intent (the “LOI”) to enter into a commercial relationship with Cannabis Manufacturer’s Guild Ltd. (“CMG”). The agreement will allow Sproutly to expand and diversify its flower and Cannabis 2.0 product offerings utilizing brands developed by CMG and its affiliates (the “Acquired Products”), through the Company’s wholly-owned subsidiary, Toronto Herbal Remedies Inc. (“THR”). Sproutly will leverage CMG’s expertise in branding, commercialization, and distribution of cannabis products for underserved categories in the Canadian market. The agreement allows Sproutly to sell the Acquired Products and facilitate potential business-to-business sales of Sproutly’s proprietary whole plant extracts to CMG’s network of Guild members.
分析記事 • Dec 02Would Sproutly Canada (CSE:SPR) Be Better Off With Less Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Nov 17Sproutly Canada, Inc. Announcea the Addition of A Supply Agreement with the Ontario Cannabis StoreSproutly Canada Inc. announced the addition of a supply agreement with the Ontario Cannabis Store ("OCS"), the Company's 6th provincial supply agreement to date. This announcement comes on the heels of the Company's October 15th announcement regarding receipt of the sales license from Health Canada for Cannabis 2.0 products directly to provinces. The Company's wholly-owned subsidiary, Toronto Herbal Remedies ("THR"), has entered into a cannabis supply agreement with the province of Ontario (the "Supply Agreement") through the OCS. Ontario will be the 6th province in Canada to carry the Company's CALIBER branded products ("CALIBER"), following Saskatchewan, Manitoba, and British Columbia earlier this year as well as Alberta & New Brunswick in 2019. With the receipt of the license amendment that now permits the Company to sell Cannabis 2.0 products, the Company is in a position to offer its full line of products to the OCS. This includes Caliber Flower, Caliber Reserve Flower and upcoming Cannabis 2.0 products that will use the Company's proprietary APP Technology to offer consumers products that aim to deliver unique experiences of different cannabis strains arising from advances in cannabis genetics.
お知らせ • Nov 10Sproutly Canada Inc. Announces Its Sixth Provincial Supply AgreementSproutly Canada Inc. announced the addition of a supply agreement with the Ontario Cannabis Store, the Company’s 6th provincial supply agreement to date. This announcement comes on the heels of the Company’s October 15th announcement regarding receipt of the sales license from Health Canada for Cannabis 2.0 products directly to provinces. The Company’s wholly-owned subsidiary, Toronto Herbal Remedies (“THR”), has entered into a cannabis supply agreement with the province of Ontario (the “Supply Agreement”) through the OCS. Ontario will be the 6th province in Canada to carry the Company’s CALIBER branded products ("CALIBER"), following Saskatchewan, Manitoba, and British Columbia earlier this year as well as Alberta & New Brunswick in 2019. With the receipt of the license amendment that now permits the Company to sell Cannabis 2.0 products, the Company is in a position to offer its full line of products to the OCS. This includes Caliber Flower, Caliber Reserve Flower and upcoming Cannabis 2.0 products that will use the Company’s proprietary APP Technology to offer consumers products that aim to deliver unique experiences of different cannabis strains arising from advances in cannabis genetics.
お知らせ • Sep 07Sproutly Canada Inc. Auditor Raises 'Going Concern' DoubtSproutly Canada Inc. filed its Annual on Aug 31, 2020 for the period ending Feb 29, 2020. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Aug 28Sproutly Canada Inc. announced that it has received CAD 0.96 million in funding from Infusion Biosciences Inc.Sproutly Canada Inc. (CNSX:SPR) announced a non-brokered private placement of 1,500,000 equity units at an issue price of 0.07 per equity unit for gross proceeds of CAD 105,000 and a secured convertible debenture for gross proceeds of CAD 855,000 and aggregate gross proceeds of CAD 960,000 on August 28, 2020. The debentures involved participation from returning investor Infusion Biosciences Inc. for CAD 855,000. The debentures carry an interest rate of 15% per annum and maturity date on or before October 24, 2020. The debenture will be convertible into debenture units a conversion price of CAD 0.07 per debt unit, subject to adjustment in accordance with the terms of the convertible debenture. Each debt unit will consist of one common share in the capital of the company and one common share purchase warrant, with each warrant entitling the investor to acquire one common share at an exercise price equal to CAD 0.08 for a period of two years from date of issuance. Each equity unit consists of one common share and one warrant, with each warrant entitling the holder to acquire one warrant share at an exercise price equal to CAD 0.08 for a period of two years from date of issuance. No finder's fees were paid in connection with the transaction. All securities issued in connection with the transaction will be subject to a four-month and one day hold period from their date of issue under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.